Form 4: Brian Atwood Reports Beneficial Ownership Changes in CERO Therapeutics Holdings

Director Brian Atwood reports exercising pre-funded warrants and directing the issuance of common stock to a trust, impacting his beneficial ownership in CERO Therapeutics Holdings.

Summary

• On March 31, 2025, Brian Atwood, a director of CERO Therapeutics Holdings, Inc., reported changes in his beneficial ownership of the company's stock.
• Atwood exercised pre-funded warrants, converting them into 294,460 shares of common stock at a price of $0.0001 per share.
• These shares were directed to the Atwood-Edminster Trust dtd 4-2-2000, for which Atwood and his wife serve as managers of the LLC and trustees.
• Following these transactions, Atwood directly owns 1,250 shares of common stock and indirectly owns 490,534 shares through the trust.
• He also directly owns 11,660 pre-funded warrants and indirectly owns 204,080 pre-funded warrants through GVN, LLC.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares, but the effect is likely negligible given the relatively small number of shares involved.

Key Dates

Keywords

beneficial ownership, CERO Therapeutics Holdings, Brian Atwood, pre-funded warrants, common stock, Form 4, director, Atwood-Edminster Trust, GVN, LLC